>

Yodfat Buchris - PROTALIX BIOTHERAP Independent Director

<div class='circular--portrait' style='background:#FF9E01;color: white;font-size:4em;padding-top: 25px;;'>PR</div>
PLX -- Israel Stock  

ILA 873.30  7.70  0.87%

  Director
Ms. Yodfat Harel Buchris is no longor serves as an Independent Director of Protalix Biotherapeutics, Inc., Effective from April 19, 2018. She has served as our director since June 2007. Since February 2014, Ms. Harel Buchris has served as the employer representative in Israels National Labor Court. She is also a Partner and a member of the board of directors of YP and 6 Partners Ltd., a business consulting and investment company. Since February 2016 she has served on the board of directors of Israel Discount Bank Limited and, since January 2016, on the board of directors of Eltek Ltd. . From 2006 to 2013, Ms. Harel Buchris served as a Managing Director of Tamares Capital Ltd., a private investment group with interests in real estate, technology, manufacturing, leisure and media. At Tamares Capital, She served as the Business Development Director and the head of the Israel office. Prior to joining Tamares Capital, from 2004 to 2006, she was the Head of the Medical Desk of Orbotech, Ltd., a company providing hightech inspection and imaging solutions for bare printed circuit board, flat panel display and PCB assembly manufacturing worldwide. Prior to that, from 1994 to 2003, she was a Managing Director of HarelHertz Investment House Ltd., a business investment company with offices in Tel Aviv, Israel and Tokyo, Japan. In 2002, HarelHertz Investment House became the Israeli representative office for ITX Corporationrationration, a publiclytraded company in Japan. Ms. Harel Buchris has served on the board of directors of Tamares Capital, Tamares Hotels, El Al, British Israel, Storewiz, Ntrig, Secure Pharma, Siklu and Tamares Telecom
Age: 44  Director Since 2007  MBA    
972 4 988 9488  http://www.protalix.com
Harel Buchris holds a B.A. in Communications and Political Science from Bar Ilan University and an executive M.B.A. from Bradford University, Great Britain. She has also completed programs in Mediation at Gome, Israel Mediation Center, Directors? Studies and Advanced Advertising and Marketing at the Israel Management Center.

Management Efficiency

The company has return on total asset (ROA) of (12.58) % which means that it has lost $12.58 on every $100 spent on asset. This is way below average.
The company has accumulated 60.92 M in total debt. PROTALIX BIOTHERAP has Current Ratio of 0.79 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Sarit FironEVOGENE LTD
2016
Ido AgmonKITOV PHARMA LTD
2016
Adina MakoverKADIMASTEM
2013
Joseph EldorKADIMASTEM
2018
Avner NavehSOLEGREEN LTD
Itai CohenSOLEGREEN LTD
2017
Daniel PelegSOLEGREEN LTD
2017
Gwen MelincoffKAMADA
2017
Kinneret SavitskyEVOGENE LTD
2010
Ronit CohenSOLEGREEN LTD
2013
Estery GilozRanKAMADA
2014
Abraham MeizlerKADIMASTEM
2014
Arie OvadiaCOMPUGEN
2007
Avi BzuraKADIMASTEM
2013
Erez BalashaSOLEGREEN LTD
2018
Julien RuggieriKADIMASTEM
2010
Yair AharonowitzCOMPUGEN
2007
David SultanKADIMASTEM
2017
Shmuel PinchasSOLEGREEN LTD
2010
Ziv KopKAMADA
2005
Shmuel RubinsteinKAMADA
2017

Company Summary

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. Protalix BioTherapeutics, Inc. was founded in 1993 and is headquartered in Karmiel, Israel. PROTALIX BIOTHERAP operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 196 people.PROTALIX BIOTHERAP (PLX) is traded on Tel Aviv Stock Exchange in Israel and employs 196 people.

PROTALIX BIOTHERAP Leadership Team

Roger Kornberg, Independent DirectorView
Yoseph Shaaltiel, Executive Vice President - Research & DevelopmentView
Shlomo Yanai, Chairman of the BoardView
Yaron Naos, Senior Vice President - OperationsView
Amos BarShalev, Independent DirectorView
Pol Boudes, DirectorView
Tzvi Palash, COOView
Dror Bashan, President, Chief Executive Officer, DirectorView
Aharon Schwartz, Independent DirectorView
Zeev Bronfeld, Independent Interim Chairman of the BoardView
Einat Almon, Senior Vice President - Product DevelopmentView
Eyal Rubin, Chief Financial Officer, Senior Vice PresidentView
Yossi Maimon, CFO, Vice President Treasurer, SecretaryView
Gwen Melincoff, DirectorView
David Granot, Independent DirectorView
Marcy Nanus, Investor ContactView
Moshe Manor, CEO and President and DirectorView
Yodfat Buchris, Independent DirectorView

Stock Performance Indicators

Current Sentiment - PLX

PROTALIX BIOTHERAP Investor Sentiment

Most of Macroaxis users are at this time bullish on PROTALIX BIOTHERAP. What is your perspective on investing in PROTALIX BIOTHERAP? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Currently Active Assets on Macroaxis

FPH   
Purchased over 40 shares of
2 days ago
Traded for 28.15
ATM   
Purchased over 100 shares of
2 days ago
Traded for 16.43
RBD   
Purchased over 20 shares of
2 days ago
Traded for 7.3
ATM   
Purchased over 40 shares of
2 days ago
Traded for 16.43
FBU   
Purchased over 200 shares of
2 days ago
Traded for 3.37
Please check Your Equity Center. Please also try Premium Stories module to follow macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page